In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $7.00. The company's shares closed yesterday at $1.93.According to TipRanks, Nakae is a 4-star analyst with an average return of 3.5% and a 37.50% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Axcella Health, Avidity Biosciences, and Alnylam Pharma.Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $8.25, a 327.46% upside from current levels. In a report released today, Wedbush also reiterated a Buy rating on the stock with a $9.
https://www.tipranks.com/news/blurbs/axcella-health-axla-receives-a-buy-from-chardan-capital-2?utm_source=advfn.com&utm_medium=referral
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to May 2023 Click Here for more Axcella Health Charts.
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From May 2022 to May 2023 Click Here for more Axcella Health Charts.